Clinical Report: Prolonged Clinical Results and Recurrence Determinants in Intracranial Germinoma
Overview
This study evaluates long-term outcomes and recurrence patterns in patients with intracranial germinoma treated at a single institution over four decades. Despite high overall survival rates, recurrence remains a significant concern, necessitating ongoing management strategies.
Background
Intracranial germinoma is a rare CNS tumor predominantly affecting children and adolescents, with a higher incidence in East Asia. It is classified as a good prognosis tumor, yet recurrence and late adverse effects from treatment pose challenges in long-term patient management. Understanding recurrence determinants is crucial for optimizing treatment strategies and improving patient outcomes.
Data Highlights
No specific numerical data was provided in the source material.
Key Findings
5- and 10-year progression-free survival rates for germinoma are reported between 78.0–91.0% and 74–96.7%, respectively.
Long-term survival rates show a decline over 30 years due to recurrence and late complications.
Whole ventricular irradiation (WVI) is the current standard treatment, with focal approaches linked to higher distant relapse rates.
Recurrence outside the irradiation field is noted, but spinal dissemination is rare.
Observational studies exceeding 10 years on long-term outcomes and recurrence risk factors are lacking.
Clinical Implications
Clinicians should prioritize long-term follow-up for patients with intracranial germinoma to monitor for recurrence and late adverse effects. Treatment strategies should focus on minimizing radiation exposure while ensuring effective tumor control, particularly through the use of whole ventricular irradiation.
Conclusion
The findings underscore the importance of long-term management in patients with intracranial germinoma, highlighting the need for ongoing research into recurrence determinants to enhance treatment protocols.
A Keck Medicine of USC neurointerventionalist discusses how a minimally invasive, endovascularly implantable cerebrospinal fluid shunt is the next-generation treatment for normal pressure hydrocephalus — and possibly more.
